leadf
logo-loader
viewAmryt Pharma PLC
(
AIM:AMYTNASDAQ:AMYTFRA:3N9
)

Amryt Pharma provides detail of Aegerion deal

The group outlined the mechanics of the transformational transaction

Amryt Pharma PLC -

Amryt Pharma PLC (LON:AMYT) has provided an update on the mechanics of its acquisition of Aegerion Pharmaceuticals Inc.

The deal will include an interim US$8mln share placing and a larger US$60mln fundraiser that will give the AIM-listed firm a pre-money valuation of US$96mln.

The merger creates a group with revenues of $136.5mln in 2018 and re-unites the Lojuxta cholesterol treatment under one roof.

The business will be bought out of Chapter 11 bankruptcy protection in a transaction backed by convertible bondholders, “certain unsecured creditors” and Nasdaq-listed Novelion Therapeutics, Aegerion’s parent company.

Turning to the nitty-gritty detail, a scheme of arrangement will be used to complete the acquisition that will insert a new English group holding company.

Rule 9 of the takeover code, which compels anyone holding more than 30% of the enlarged business to bid for the firm, is expected to be waived.

Stock in the merged companies will be listed on AIM and the Euronext Growth exchanges. The shares have restarted trading after a one-for-six consolidation and are currently changing hands for 112.1p.

For full transaction details, click here.

Quick facts: Amryt Pharma PLC

Follow
AIM:AMYT

Price: 174.15 GBX

Market Cap: £551.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt reports record 2Q results and raises full-year guidance as momentum...

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company's second-quarter results, which show a 35.9% rise in revenue year-on-year. Wiley noting that it's the sixth consecutive quarter the company has reported positive EBITDA...

on 6/8/21

2 min read